Loading patent…
AssigneeOncotherapy Science, Inc.
InventorsTakuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura
Estimating the term…
The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.
A method of treating a cancer expressing URLC10 and HLA-A2 in a subject, said method comprising administering to said subject a composition comprising a peptide selected from the group consisting of the following (i) and (ii), or a polynucleotide encoding said peptide:
A method of treating cancer expressing URLC10 and HLA-A2 in a subject, said method comprising administering to said subject a composition comprising a peptide selected from the group consisting of following (i) and (ii) or a polynucleotide encoding said peptide:
Dependencies are inferred from the claim text.